Lapix Therapeutics
Lapix Therapeutics: Enhancing immune response and drug safety through targeted therapeutic modulation.
Founded
2020Lapix Therapeutics: Enhancing immune response and drug safety through targeted therapeutic modulation.
Lapix Therapeutics, founded with a mission to restore immune balance and transform lives, is a clinical-stage biopharmaceutical company focused on innovative treatments for autoimmune diseases. The company aims to treat the root causes of these diseases rather than just alleviating symptoms. Lapix Therapeutics specializes in developing novel, orally administered therapies that modulate the immune system to delay disease onset, sustain therapeutic response, and enhance the safety of partner drugs.
Notable figures affiliated with Lapix Therapeutics include leading immunologists and biopharmaceutical experts. The company has attracted significant investment from prominent venture capital firms specializing in healthcare and biotechnology. Key achievements include advancing multiple first-in-class treatments into clinical trials, demonstrating promising efficacy and safety profiles. Lapix Therapeutics has made a substantial impact by offering new hope to patients with autoimmune diseases through its patient-centric and innovative approach to immune system modulation.
Companies similar to Lapix Therapeutics include IpiNovyx Bio, Asylia Therapeutics, Rise Therapeutics and SFA Therapeutics.
Lapix Therapeutics was founded in 2020.
Lapix Therapeutics' headquarters is located in Boston, MA, US.
Lapix Therapeutics' most recent funding round was for $5.9M (USD) in April 2023.
As of Apr 27, 2023, Lapix Therapeutics has raised a total of $5.9M (USD).
Lapix Therapeutics has 9 employees as of Feb 5, 2024.
Rise Therapeutics
